PPIDT00383
Drug Information
| Name | Burosumab |
|---|---|
| Sequence | QVQLVQSGAEVKKPGASVKVSCKASGYTFTNHYMHWVRQAPGQGLEWMGIINPISGSTSNAQKFQGRVTMTRDTSTSTVYMELSSLRSEDTAVYYCARDIVDAFDFWGQGTMVTVSSASTKGPSVFPLAPSSKSTSGGTAALGCLVKDYFPEPVTVSWNSGALTSGVHTFPAVLQSSGLYSLSSVVTVPSSSLGTQTYICNVNHKPSNTKVDKKVEPKSCDKTHTCPPCPAPELLGGPSVFLFPPKPKDTLMISRTPEVTCVVVDVSHEDPEVKFNWYVDGVEVHNAKTKPREEQYNSTYRVVSVLTVLHQDWLNGKEYKCKVSNKALPAPIEKTISKAKGQPREPQVYTLPPSRDELTKNQVSLTCLVKGFYPSDIAVEWESNGQPENNYKTTPPVLDSDGSFFLYSKLTVDKSRWQQGNVFSCSVMHEALHNHYTQKSLSLSPGK |
| DrugBank_ID | DB14012 |
| Type | biotech |
| Indication | This drug is indicated for the treatment of X-linked hypophosphatemia with radiological evidence of bone disease in children of 1 year of age and older and adolescents with growing skeletons [L2347]. |
Dosage Forms
| Form | Route | Strength |
|---|---|---|
| Injection | Subcutaneous |
10 mg/1mL
|
| Injection | Subcutaneous |
20 mg/1mL
|
| Injection | Subcutaneous |
30 mg/1mL
|
| Injection, solution | Subcutaneous |
10 mg/mL
|
| Injection, solution | Subcutaneous |
20 mg/mL
|
| Injection, solution | Subcutaneous |
30 mg/mL
|
| Solution | Subcutaneous |
10 mg / mL
|
| Solution | Subcutaneous |
20 mg / mL
|
| Solution | Subcutaneous |
30 mg / mL
|
| Solution | Subcutaneous |
10 mg
|
| Solution | Subcutaneous |
1000000 mg
|
| Solution | Subcutaneous |
20 mg
|
| Solution | Subcutaneous |
2000000 mg
|
| Solution | Subcutaneous |
30 mg
|
| Solution | Subcutaneous |
3000000 mg
|